GDRX Stock Price Forecast

 

GDRX is currently trading near the low end of its multi-year range after a difficult reset in its prescription transaction business, but analysts still see moderate upside potential if the company can stabilize growth and expand higher-margin services like Pharma Direct and subscriptions.

2026–2027 Forecast Outlook

• Base case: $3.50–$4.25 over the next 12 months if execution improves and revenue guidance holds.
• Bullish case: $5–$6 if Pharma Direct growth continues above expectations and margins recover.
• Bearish case: $1.80–$2.40 if prescription transaction declines accelerate or pharmacy/PBM pressures worsen.

What Analysts Are Watching

• Q1 2026 revenue came in at about $194M, beating expectations slightly.
• Pharma Direct revenue surged 82% year over year, showing strong growth in newer business segments.
• Full-year 2026 guidance was raised to roughly $765M–$785M revenue with adjusted EBITDA above $235M.
• Wall Street consensus remains mostly “Hold”, with average price targets around $3.75–$3.85.

Technical Perspective

The stock remains in a longer-term downtrend, but recent earnings strength created a possible reversal setup:

• Resistance zones: $3.20 → $3.85 → $5.00
• Support zones: $2.40 → $2.00
• A sustained move above $3.20 could improve momentum significantly.

Overall View

GDRX currently looks more like a turnaround/speculative growth play than a stable healthcare stock. The company still has:

• strong consumer brand recognition,
• improving subscription revenue,
• and significant healthcare pricing demand,

but investor confidence depends on whether management can offset declining legacy prescription transaction revenue with newer higher-growth services.